ClinicalTrials.gg

Program

opnurasib

Also written as “JDQ443” and “Opnurasib”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Lung Neoplasms · Small Cell Lung Carcinoma, led by Novartis.

Furthest: phase 3, since Nov 11, 20215 company-led studies, 3 open or runningNext primary completion: Jan 25, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis53 open or runningphase 3since Nov 11, 2021Jan 5, 2021Jan 25, 2027phase 2 · NCT04699188

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 5, 2021First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT04699188 · 344 enrolled · United States, Australia, Belgium and more
  2. Nov 11, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05132075 · 95 enrolled · United States, Argentina, Australia and more
  3. Mar 29, 2022Phase 1 study in Small Cell Lung CarcinomaNCT05329623 · 33 enrolled · United States
  4. Jun 30, 2022Phase 2 study in Lung NeoplasmsNCT05445843 · 95 enrolled · United States, Argentina, Austria and more
  5. Mar 9, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07468071 · 25 enrolled · Belgium, Canada, China and more
  6. Nov 6, 2026Phase 3 study terminatedStudy stoppedNCT05132075 · “Business reasons and not based on any safety concerns.”

Ahead

  1. Jan 25, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT04699188
  2. Jun 11, 2029Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07468071

TargetBeta

KRAS →read by rule
“An inhibitor of the oncogenic KRAS substitution mutation, G12C, ”NCIt, by rule

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
adagrasibruleBristol-Myers Squibbphase 316
olomorasibEli Lillyphase 316
divarasibHoffmann-La Rochephase 313
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 312
glecirasibruleAllist Pharmaceuticalsphase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07468071Carcinoma, Non-Small-Cell Lung · Belgium, Canada, China and more2Active, not recruitingJun 11, 202925
NCT05445843Lung Neoplasms · United States, Argentina, Austria and more2Active, not recruitingNov 4, 202495
NCT05329623Small Cell Lung Carcinoma · United States1CompletedApr 7, 202433
NCT05132075Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3TerminatedSep 3, 202695
NCT04699188Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more2Active, not recruitingJan 25, 2027344

How it is read

Names in the registry

  • “JDQ443”, 4 entries
  • “Opnurasib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.